Altimmune, Inc. (ALT) stock plummeted 10.64% during Friday's intraday trading session despite the company presenting encouraging new data from its Phase 1b trial of pemvidutide in metabolic dysfunction-associated steatotic liver disease (MASH).
The data, presented at The Liver Meeting® 2024 of the American Association for the Study of Liver Diseases, showed that once-weekly subcutaneous doses of pemvidutide resulted in significant reductions in multiple classes of inflammatory lipids associated with increased cardiovascular disease risk and atherosclerosis progression.
Specifically, pemvidutide rapidly and markedly reduced levels of small atherogenic LDL particles compared to placebo in MASH patients with overweight or obesity. These findings suggest pemvidutide could potentially help address major comorbidities of MASH beyond just reducing liver fat, such as cardiovascular disease, atherosclerosis, and metabolic syndrome.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。